Updated advice on COVID-19 vaccination in pregnancy and women who are breastfeeding, RCOG
The Government has today accepted the recommendation from the Medicines and Healthcare products Regulatory Agency (MHRA) to authorise Oxford University/AstraZeneca's COVID-19 vaccine for use. The Joint Committee on Vaccination and Immunisation (JCVI) has also published its latest advice for the priority groups to receive the Oxford University/AstraZeneca and the Pfizer/BioNTech vaccines. This includes updated advice for pregnant and breastfeeding women who meet other criteria for priority vaccination. The JCVI confirms that although the available data do not indicate any safety concern or harm to pregnancy, there is insuf...
Source: Current Awareness Service for Health (CASH) - December 31, 2020 Category: Consumer Health News Source Type: news

Antifungal drug improves key cystic fibrosis biomarkers in clinical study
(University of Illinois at Urbana-Champaign, News Bureau) A drug widely used to treat fungal infections improved key biomarkers in lung tissue cultures as well as in the noses of patients with cystic fibrosis, a clinical study by researchers at the University of Illinois Urbana-Champaign and the University of Iowa found. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - December 17, 2020 Category: Biology Source Type: news

Featured Review: Drugs for correcting the basic defect in the most common cystic fibrosis-causing gene variant
Read thisrecently published Cochrane review about CFTR correctors, a therapy for cystic fibrosis targeted at specific variants (most commonly F508del)In this review, the authors looked at drugs (or drug combinations) for correcting the basic defect in the most common cystic fibrosis (CF)-causing gene variant (F508del) and assessed their impact on outcomes important to people with Cystic Fibrosis, e.g. survival, quality of life (QoL), lung function and safety.Professor Kevin Southern, lead author of this review, has been involved in the care of children with CF for over 30 years, and has a deep appreciation of the impact of...
Source: Cochrane News and Events - December 16, 2020 Category: Information Technology Authors: Katie Abbotts Source Type: news

How Is a Person's Life Affected By Cystic Fibrosis?
Title: How Is a Person's Life Affected By Cystic Fibrosis?Category: Diseases and ConditionsCreated: 10/9/2020 12:00:00 AMLast Editorial Review: 12/10/2020 12:00:00 AM (Source: MedicineNet Lungs General)
Source: MedicineNet Lungs General - December 10, 2020 Category: Respiratory Medicine Source Type: news

Johns Hopkins develops potential antibiotic for drug-resistant pathogen
(Johns Hopkins University) Scientists from Johns Hopkins University and Medicine have developed a possible new antibiotic for a pathogen that is notoriously resistant to medications and frequently lethal for people with cystic fibrosis and other lung ailments. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 8, 2020 Category: International Medicine & Public Health Source Type: news

FDA approves Xolair ® (omalizumab) for adults with nasal polyps
             Basel, 01 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved the company ’s supplemental Biologics License Application (sBLA) for Xolair® (omalizumab) for the add-on maintenance treatment of nasal polyps in adult patients 18 years of age and older with inadequate response to nasal corticosteroids.1 Nasal polyps can lead to a loss of smell and nasal congestion, and frequently co-occur with other respiratory conditions, such as allergies and asthma. With this ap...
Source: Roche Media News - December 1, 2020 Category: Pharmaceuticals Source Type: news

FDA approves Xolair ® (omalizumab) for adults with nasal polyps
             Basel, 01 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved the company ’s supplemental Biologics License Application (sBLA) for Xolair® (omalizumab) for the add-on maintenance treatment of nasal polyps in adult patients 18 years of age and older with inadequate response to nasal corticosteroids.1 Nasal polyps can lead to a loss of smell and nasal congestion, and frequently co-occur with other respiratory conditions, such as allergies and asthma. With this ap...
Source: Roche Investor Update - December 1, 2020 Category: Pharmaceuticals Source Type: news

Telehealth Finds Acceptance Among Patients With Cf, Clinicians Telehealth Finds Acceptance Among Patients With Cf, Clinicians
Telehealth is widely accepted among individuals with cystic fibrosis (CF) and the physicians who treat them, according to three new studies.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 23, 2020 Category: Consumer Health News Tags: Pulmonary Medicine News Source Type: news

COVID-19 rapid guideline: cystic fibrosis, NICE (updated 7th October 2020)
The purpose of this guideline is to maximise the safety of patients with cystic fibrosis and make the best use of NHS resources, while protecting staff from infection.The guideline focuses on what you need to stop or start doing during the pandemic. Follow the usual professional guidelines, standards and laws (including those on equalities, safeguarding, communication and mental capacity), as described in 2 External 0 0 0 making decisions using NICE guidelines false https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-guidelines/making-decisions-using-nice-guidelines true false%>. On 7 October 2020...
Source: Current Awareness Service for Health (CASH) - November 20, 2020 Category: Consumer Health News Source Type: news

Why Is Meconium Ileus Diagnostic for Cystic Fibrosis?
Title: Why Is Meconium Ileus Diagnostic for Cystic Fibrosis?Category: Procedures and TestsCreated: 11/20/2020 12:00:00 AMLast Editorial Review: 11/20/2020 12:00:00 AM (Source: MedicineNet Kids Health General)
Source: MedicineNet Kids Health General - November 20, 2020 Category: Pediatrics Source Type: news

Understanding lung infections in patients with cystic fibrosis
(University of Warwick) For young people with cystic fibrosis, lung infection with Staphylococcus aureus, MRSA, is common and is treated with antibiotics in the hope that this will prevent a decline in lung function. However there has recently been debate over the role S. aureus plays in CF lung disease. Researchers from the University of Warwick have used a new model of CF lungs which could be used to make better decisions about future use of antibiotics. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - November 19, 2020 Category: Infectious Diseases Source Type: news

Former Gilead CEO lands on board of East Bay gene therapy company seeking $75M IPO
4D Molecular Therapeutics' gene therapies are mainly focused on the eyes, but includes potential one-and-done treatments for Fabry disease and cystic fibrosis. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - November 18, 2020 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news

Former Gilead CEO lands on board of East Bay gene therapy company seeking $75M IPO
4D Molecular Therapeutics' gene therapies are mainly focused on the eyes, but includes potential one-and-done treatments for Fabry disease and cystic fibrosis. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - November 18, 2020 Category: American Health Authors: Ron Leuty Source Type: news

Cystic Fibrosis Patients' Vulnerability to COVID-19 Infection Cystic Fibrosis Patients' Vulnerability to COVID-19 Infection
Clinicians treating patients with cystic fibrosis have had to face the possibility that their patients may be at greater risk of worse outcomes from COVID-19.Medscape Medical News (Source: Medscape Emergency Medicine Headlines)
Source: Medscape Emergency Medicine Headlines - November 11, 2020 Category: Emergency Medicine Tags: Pulmonary Medicine News Source Type: news

Respiratory platform NuvoAir shows high acceptance of its home spirometry
The platform has shared three studies presented at the 2020 North American Cystic Fibrosis (CF) conference. (Source: mobihealthnews)
Source: mobihealthnews - November 9, 2020 Category: Information Technology Source Type: news

Triple Combination Benefits CF Patients With Advanced Disease Triple Combination Benefits CF Patients With Advanced Disease
Triple combination therapy in cystic fibrosis patients with advanced lung disease appears to improve lung function, and may delay the need for lung transplant.Medscape Medical News (Source: Medscape Infectious Diseases Headlines)
Source: Medscape Infectious Diseases Headlines - November 6, 2020 Category: Infectious Diseases Tags: Pulmonary Medicine News Source Type: news

Genetic mutation could worsen heart function in Duchenne muscular dystrophy patients
(UT Southwestern Medical Center) DALLAS - Nov. 4, 2020 - A mutation in the gene that causes cystic fibrosis may accelerate heart function decline in those with Duchenne muscular dystrophy (DMD), a new study by UT Southwestern researchers suggests. The findings, published online recently in theJournal of the American Heart Association, could help doctors develop new strategies to preserve heart function in this population, potentially extending patients' lives. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 4, 2020 Category: International Medicine & Public Health Source Type: news

FDA Approves Bronchitol (mannitol) Inhalation Powder to Improve Pulmonary Function in Adult Patients with Cystic Fibrosis
CARY, N.C., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Chiesi USA, Inc., the U.S. affiliate of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), received U.S. Food and Drug Administration (FDA) approval of... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 2, 2020 Category: Drugs & Pharmacology Source Type: news

Let's (not) stick together
(University of Pittsburgh) New research led by the University of Pittsburgh's Swanson School of Engineering examines the properties of the mucus of cystic fibrosis (CF) patients and the role it plays in a pathogens' ability to survive. The new information could have important implications for CF treatment. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 28, 2020 Category: International Medicine & Public Health Source Type: news

Armata Pharmaceuticals Appoints Mina Pastagia, MD, MS as Vice President of Clinical Development
Appointment adds extensive expertise in the development of anti-infectives, including bacteriophage therapy to treat P. aeruginosa infections in cystic fibrosis patients MARINA DEL REY, Calif., Oct. 26, 2020 -- (Healthcare Sales & Marketing Network) --... Biopharmaceuticals, Personnel Armata Pharmaceuticals, bacteriophage therapeutics (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 26, 2020 Category: Pharmaceuticals Source Type: news

Twin left fighting for his life with cystic fibrosis has finally got £28,000 drug that will save him
Anthony Usher, from Liverpool, has cystic fibrosis, an incurable genetic condition that destroys the lungs and digestive system. (Source: the Mail online | Health)
Source: the Mail online | Health - October 24, 2020 Category: Consumer Health News Source Type: news

Researchers create human airway stem cells from patients' cells
(Boston Medical Center) For the first time, researchers have successfully created airway basal stem cells in vitro from induced pluripotent stem cells by reprogramming blood cells taken from patients. Given that airway basal cells are defined as stem cells of the airways because they can regenerate the airway epithelium in response to injury, this study may help accelerate research on diseases impacting the airway, including COVID-19, influenza, asthma and cystic fibrosis. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 23, 2020 Category: International Medicine & Public Health Source Type: news

Thirona obtains AI software patent for treatment of cystic fibrosis in children
The AI company will use the license to implement  a quantitative method for the analysis of chest CT scans. (Source: mobihealthnews)
Source: mobihealthnews - October 16, 2020 Category: Information Technology Source Type: news

Cystic fibrosis latest: New wonder drug Kaftrio gives hope to sufferers
Cystic fibrosis wonder drug Kaftrio is now being rolled out across the UK and today the Daily Express brings you the stories of renewed hope as sufferers reveal how it will transform their lives. (Source: Daily Express - Health)
Source: Daily Express - Health - October 11, 2020 Category: Consumer Health News Source Type: news

IV, Oral Antibiotics Comparable for Treating P. aeruginosa in CF
Results do not support use of IV antibiotics to eradicate P. aeruginosa in cystic fibrosis, authors say (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - October 8, 2020 Category: Respiratory Medicine Tags: Family Medicine, Infections, Internal Medicine, Pediatrics, Pharmacy, Pulmonology, Journal, Source Type: news

IV, Oral Antibiotics Comparable for Treating P. aeruginosa in CF
THURSDAY, Oct. 8, 2020 -- Intravenous antibiotics do not achieve greater sustained eradication of Pseudomonas aeruginosa in patients with cystic fibrosis compared with oral therapy, according to a study published in the October issue of The Lancet... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 8, 2020 Category: Pharmaceuticals Source Type: news

Treating cystic fibrosis with mRNA therapy or CRISPR
(Mary Ann Liebert, Inc./Genetic Engineering News) The potential for treating cystic fibrosis (CF) using mRNA therapies or CRISPR gene editing is possible regardless of the causative mutation. CF clinical trials showing that a genotype-agnostic gene therapy for CF is possible (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 8, 2020 Category: International Medicine & Public Health Source Type: news

COVID-19 rapid guideline: cystic fibrosis [NG170], NICE (updated 7th October 2020)
On 7 October 2020, we withdrew our recommendations on reducing or deprioritising cystic fibrosis registry data entry, limiting transplant services and deferring transition to adult services because these emergency measures are no longer needed. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - October 7, 2020 Category: Consumer Health News Source Type: news

DDT COA #000007: The Cystic Fibrosis Respiratory Symptom Diary – Chronic Respiratory Infection Symptom Score (CFRSD-CRISS)
Clinical Outcome Assessments (COA) Qualification Submissions Office of Antimicrobial Products (OAP) Division of Anti-Infective Products (DAIP) DDT COA Number DDT COA #000007 (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - October 7, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Thirona licenses patent for cystic fibrosis AI software
Dutch artificial intelligence (AI) software developer Thirona said it has exclusively...Read more on AuntMinnie.comRelated Reading: Thirona, Smart Reporting team up on COVID-19 software Free AI software can help triage COVID-19 on x-ray Thirona unveils AI software for COVID-19 analysis (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - October 6, 2020 Category: Radiology Source Type: news

Can You Live A Long Life with Cystic Fibrosis
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - September 30, 2020 Category: General Medicine Source Type: news

Landmark clinical trial shows effectiveness of oral antibiotics in treating cystic fibrosis condition
(University of Nottingham) A major national study led by experts from Bristol and Nottingham has found that oral antibiotics are just as effective as intravenous antibiotics in killing a common germ that causes dangerous complications in cystic fibrosis (CF) patients. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 29, 2020 Category: International Medicine & Public Health Source Type: news

Mayo Clinic Q and A: Cystic fibrosis and COVID-19
DEAR MAYO CLINIC: My cousin has cystic fibrosis. After graduating from college last December, she moved across the country to take a new job. Now she lives with me. I have always been worried about her, but I am more concerned now that COVID-19 cases are rising in our area. Although I know coughing is common [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - September 28, 2020 Category: Databases & Libraries Source Type: news

FDA Approves Kalydeco (ivacaftor) as First and Only CFTR Modulator to Treat Eligible Infants With CF as Early as Four Months of Age
BOSTON--(BUSINESS WIRE)--Sep. 25, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) approved Kalydeco (ivacaftor) for use in children with cystic fibrosis (CF) ages four months to... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - September 25, 2020 Category: Drugs & Pharmacology Source Type: news

Cystic Fibrosis and COVID-19 Cystic Fibrosis and COVID-19
Although many physicians believed that cystic fibrosis patients would be hard-hit by COVID-19, that has not happened. How has this group managed the pandemic so well?Southern Medical Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 23, 2020 Category: Consumer Health News Tags: Family Medicine/Primary Care Journal Article Source Type: news

Cystic Fibrosis: The Cribsiders' Update Cystic Fibrosis: The Cribsiders' Update
Presentation of CF, airway clearance regimens, diabetes in CF, and other highlights from the cystic fibrosis episode of The Cribsiders podcast.Medscape Pediatrics (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - September 21, 2020 Category: Allergy & Immunology Tags: Pediatrics Commentary Source Type: news

How Long Can You Live With Cystic Fibrosis?
Title: How Long Can You Live With Cystic Fibrosis?Category: Diseases and ConditionsCreated: 9/16/2020 12:00:00 AMLast Editorial Review: 9/16/2020 12:00:00 AM (Source: MedicineNet Womens Health General)
Source: MedicineNet Womens Health General - September 16, 2020 Category: OBGYN Source Type: news

Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis
Current evidence, limited to one RCT (n=132), is insufficient to determine effect of choosing antibiotics based on combination antimicrobial susceptibility testing vs conventional antimicrobial susceptibility testing. Further investigation is required. This is an updated version of a previously published review. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - September 15, 2020 Category: Consumer Health News Source Type: news

New method of detecting illnesses including coronavirus and cystic fibrosis
(University of Leeds) A new and quicker method of diagnosing diseases in patients has been created by researchers. The team has developed a system of examining individual molecules to detect the presence of disease in blood. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - September 2, 2020 Category: Infectious Diseases Source Type: news

Ivacaftor not cost effective in cystic fibrosis with G551D mutation
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - August 31, 2020 Category: Drugs & Pharmacology Source Type: news

Delayed access to cystic fibrosis drug could result in preventable death: study
(Source: St. Michael's Hospital News and Media)
Source: St. Michael's Hospital News and Media - August 24, 2020 Category: Hospital Management Tags: Hospital News Source Type: news

Landmark NHS deal to open up access to life-changing cystic fibrosis drug
NHS patients will be among the first in Europe to be prescribed Kaftrio, which significantly improves lung function, helping people with cystic fibrosis to breathe more easily and enhancing their overall quality of life. (Source: NHS Networks)
Source: NHS Networks - August 23, 2020 Category: UK Health Source Type: news

Allergen-specific igG4 response to recombinant aspergillus fumigatus allergens in patients with non-cystic fibrosis bronchiectasis
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - August 22, 2020 Category: Respiratory Medicine Authors: MeganB Source Type: news

Heel-prick blood test could predict type 1 diabetes in children
Heel-prick tests are already used in Britain to check for nine rare but serious conditions, including cystic fibrosis and sickle cell disease. Scientists are pushing for diabetes to be added. (Source: the Mail online | Health)
Source: the Mail online | Health - August 10, 2020 Category: Consumer Health News Source Type: news

Boston Hospitals To Test Cystic Fibrosis Drug On Severely Ill Coronavirus Patients
BOSTON (CBS) — Harvard University researchers are working with two Boston hospitals to try a new way to help the sickest coronavirus patients. Boston Children’s Hospital and Brigham and Women’s Hospital will test a drug approved by the FDA to treat people with cystic fibrosis on those experiencing severe COVID-19 pneumonia and respiratory failure. The drug is called Dornase alfa, also known as DNase 1 or Pulmozyme, and it works to prevent lung infections by breaking up thick mucus. That may make oxygen easier to deliver via ventilator, researchers say. There’s also hope that the drug might break up ...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - August 7, 2020 Category: Consumer Health News Authors: Health – CBS Boston Tags: Boston News Covid-19 Boston, MA Health Syndicated CBSN Boston Syndicated Local Boston Children's Hospital Brigham and Women's Hospital Coronavirus Harvard University Source Type: news

Randomized study for treatment of COVID pneumonia uses cystic fibrosis drug dornase alfa
(Boston Children's Hospital) Researchers at Boston Children's Hospital and Brigham and Women's Hospital have launched a randomized, placebo-controlled clinical trial of dornase alfa (Pulmozyme) in patients with severe COVID-19 pneumonia and respiratory failure requiring mechanical ventilation. The study aims to enroll 60 adults and children (over age 3) admitted to intensive care units. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 28, 2020 Category: International Medicine & Public Health Source Type: news

GlycoNet invests $3.9 million to address research gaps in Canadian healthcare
(Canadian Glycomics Network) The Canadian Glycomics Network (GlycoNet) today awarded $3.9 million in grant funding to 11 collaborative research projects. The fund will support a wide range of multidisciplinary research teams across 17 Canadian research institutions and their industry partners to address unmet medical needs in cancer, gastrointestinal inflammations, cystic fibrosis, Sanfillipo disease, Parkinson's, and autoimmune diseases. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 23, 2020 Category: Cancer & Oncology Source Type: news

CFHealthHub for managing cystic fibrosis during the COVID-19 pandemic - Medtech innovation briefing (MIB219), NICE (published 10th July 2020)
CFHealthHub is a digital platform to help adults with cystic fibrosis manage their condition and monitor their medicine use. Evidence from a randomised feasibility study and two economic studies is discussed; the results of a UK RCT (n=607) are due for publication later this year (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - July 13, 2020 Category: Consumer Health News Source Type: news

Cystic fibrosis: why so many respiratory complications?
(Universit é de Gen è ve) Cystic fibrosis, one of the most common genetic diseases in Switzerland, causes severe respiratory and digestive disorders. Despite considerable therapeutic advances, this disease still reduces life expectancy, in particular due to life-threatening respiratory infections. Scientists from the University of Geneva (UNIGE) have discovered the reason for this large number of lung infections: a protein, Vav3. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 13, 2020 Category: International Medicine & Public Health Source Type: news

BARNEY CALMAN: Cystic fibrosis sufferers finally get 'wonder drug' after endless talks
Over the past six months, the MoS has lifted the lid on the secretive talks between NHS England and drug company Vertex on access to cystic fibrosis drugs. (Source: the Mail online | Health)
Source: the Mail online | Health - July 4, 2020 Category: Consumer Health News Source Type: news